CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
New York, New York, United States and 213 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Mineola, New York, United States and 125 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
New York, New York, United States and 41 other locations
be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...
Phase 1, Phase 2
New York, New York, United States and 8 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
New York, New York, United States and 46 other locations
clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian...
Phase 1, Phase 2
New York, New York, United States and 18 other locations
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Ridgewood, New Jersey, United States and 20 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
New York, New York, United States and 70 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
New York, New York, United States and 93 other locations
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-...
Phase 1
New York, New York, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal